bicifadine
Small moleculeexperimental
Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00295711)
Timeline
Indications
Mechanism of action
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
- Monoamine transporterINHIBITOR
Monoamine transporter inhibitor
Norepinephrine > serotonin > dopamine (approximately 1:2:17)
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C23CNCC2C3)cc1- Mol. weight
- 173.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBicifadine ↗
- ChEMBLCHEMBL511099 ↗
Also known as
- bicifadine
- bicifadine
- bicifadine
- bicifadine
- bicifadine hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00597649 | Phase 2 | Oct 1, 2007 | XTL Biopharmaceuticals |
| NCT00553592 | Phase 2 | Sep 1, 2007 | XTL Biopharmaceuticals |
| NCT00295724 | Phase 3 | Oct 1, 2005 | DOV Pharmaceutical, Inc. |
| NCT00281645 | Phase 3 | Dec 1, 2004 | DOV Pharmaceutical, Inc. |
| NCT00295711 | Phase 3 | Sep 1, 2004 | DOV Pharmaceutical, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DOV Pharmaceutical, Inc. | For profit | 3 | 3 | 1 | 2004 |
| XTL Biopharmaceuticals | For profit | 2 | 2 | 1 | 2007 |
2 organizations
Page 1 / 1